About us
PharmaPlus Consultancy is an experienced advisor on pre-commercial stage biopharmaceutical in-licensing and out-licensing. We bring value to all stages of licensing transactions.
Our offer
We identify, analyze, commercialize and evaluate potential biopharmaceutical licensing opportunities.
Out-licensing biopharmaceutical assets and technology for SME as well as startup companies. In-licensing technology scouting for startups, SME, medium-sized and big pharmaceutical companies. Our approach is always tailored specifically to your needs. We offer our services on a regional or worldwide basis.
Our focus
Our experience covers multiple disease areas, including autoimmune disorders, blood & blood forming organs, bone disorders, cardiovascular disorders, CNS disorders, dermatology, eye disorders, gastrointestinal disorders, genetic disorders, infectious diseases, inflammatory disorders, kidney disorders, musculoskeletal disorders, oncology, respiratory disorders, transplantation, vaccines, antibody technologies, cell therapy, and radiopharmaceuticals.
Given the nature of our work, our client activities are strictly confidential. Therefore, we do not disclose client names.
Founder
Karin Bakker is founder and principal of PharmaPlus Consultancy. She is a seasoned business development executive with both scientific and business knowledge and more than 25 years experience in business development, in-/out-licensing, technology scouting and licensing deals benchmarking for pre-commercial stage (bio)pharmaceuticals.
Since 1996 Karin has consulted for a large variety of organizations with an interest in the life science sector. She approaches engagements with professionalism and persistence to help achieve performance on behalf of clients. Karin has concluded multiple regional and worldwide biotechnology and pharma deals for amongst others antibodies, cell therapy, drug conjugates, peptides and small molecules.
Previously Karin co-founded consultancy company Bakker & Pronk, delivering project management, disease management, reimbursement services and market studies for the Dutch market to clients like ALK-Abelló, Alliance Boots, Merck Organon (Merck & Co) Merck Serono and Sanofi.
Karin worked at NPBI (Fresenius), where she was responsible for international business development and project management and facilitated the company’s first licensing deal for the US market. Karin is a pharmacist.